O	0	6	Impact
O	7	9	of
O	10	11	a
B-intervention	12	18	higher
I-intervention	19	28	radiation
I-intervention	29	33	dose
O	34	36	on
O	37	42	local
O	43	50	control
O	51	54	and
O	55	63	survival
O	64	66	in
O	67	73	breast
O	73	74	-
O	74	84	conserving
O	85	92	therapy
O	93	95	of
O	96	101	early
O	102	108	breast
O	109	115	cancer
O	115	116	:
O	117	119	10
O	119	120	-
O	120	124	year
O	125	132	results
O	133	135	of
O	136	139	the
O	140	150	randomized
O	151	156	boost
O	157	163	versus
O	164	166	no
O	167	172	boost
O	173	178	EORTC
O	179	184	22881
O	184	185	-
O	185	190	10882
O	191	196	trial
O	196	197	.

O	198	200	To
O	201	212	investigate
O	213	216	the
O	217	221	long
O	221	222	-
O	222	226	term
O	227	233	impact
O	234	236	of
O	237	238	a
O	239	244	boost
O	245	254	radiation
O	255	259	dose
O	260	262	of
O	263	265	16
O	266	268	Gy
O	269	271	on
O	272	277	local
O	278	285	control
O	285	286	,
O	287	295	fibrosis
O	295	296	,
O	297	300	and
O	301	308	overall
O	309	317	survival
O	318	321	for
O	322	330	patients
O	331	335	with
O	336	341	stage
O	342	343	I
O	344	347	and
O	348	350	II
O	351	357	breast
O	358	364	cancer
O	365	368	who
O	369	378	underwent
O	379	385	breast
O	385	386	-
O	386	396	conserving
O	397	404	therapy
O	404	405	.

O	406	407	A
O	408	413	total
O	414	416	of
B-total-participants	417	418	5
I-total-participants	418	419	,
I-total-participants	419	422	318
B-eligibility	423	431	patients
I-eligibility	432	436	with
I-eligibility	437	452	microscopically
I-eligibility	453	461	complete
I-eligibility	462	470	excision
I-eligibility	471	479	followed
I-eligibility	480	482	by
I-eligibility	483	488	whole
I-eligibility	488	489	-
I-eligibility	489	495	breast
I-eligibility	496	507	irradiation
I-eligibility	508	510	of
I-eligibility	511	513	50
I-eligibility	514	516	Gy
O	517	521	were
O	522	530	randomly
O	531	539	assigned
O	540	542	to
O	543	550	receive
O	551	557	either
O	558	559	a
O	560	565	boost
O	566	570	dose
O	571	573	of
O	574	576	16
O	577	579	Gy
O	580	581	(
B-intervention-participants	581	582	2
I-intervention-participants	582	583	,
I-intervention-participants	583	586	661
O	587	595	patients
O	595	596	)
O	597	599	or
B-control	600	602	no
I-control	603	608	boost
I-control	609	613	dose
O	614	615	(
B-control-participants	615	616	2
I-control-participants	616	617	,
I-control-participants	617	620	657
O	621	629	patients
O	629	630	)
O	630	631	,
O	632	636	with
O	637	638	a
O	639	645	median
O	646	652	follow
O	652	653	-
O	653	655	up
O	656	658	of
O	659	661	10
O	661	662	.
O	662	663	8
O	664	669	years
O	669	670	.

O	671	674	The
O	675	681	median
O	682	685	age
O	686	689	was
B-age	690	692	55
I-age	693	698	years
O	698	699	.

B-outcome	700	705	Local
I-outcome	706	716	recurrence
O	717	720	was
O	721	729	reported
O	730	732	as
O	733	736	the
O	737	742	first
O	743	752	treatment
O	753	760	failure
O	761	763	in
B-cv-bin-abs	764	767	278
O	768	776	patients
O	777	781	with
O	782	784	no
O	785	790	boost
O	791	797	versus
B-iv-bin-abs	798	801	165
O	802	810	patients
O	811	815	with
O	816	821	boost
O	821	822	;
O	823	825	at
B-outcome	826	828	10
I-outcome	829	834	years
O	834	835	,
O	836	839	the
B-outcome	840	850	cumulative
I-outcome	851	860	incidence
I-outcome	861	863	of
I-outcome	864	869	local
I-outcome	870	880	recurrence
O	881	884	was
B-cv-bin-percent	885	887	10
I-cv-bin-percent	887	888	.
I-cv-bin-percent	888	889	2
I-cv-bin-percent	889	890	%
O	891	897	versus
B-iv-bin-percent	898	899	6
I-iv-bin-percent	899	900	.
I-iv-bin-percent	900	901	2
I-iv-bin-percent	901	902	%
O	903	906	for
O	907	910	the
O	911	913	no
O	914	919	boost
O	920	923	and
O	924	927	the
O	928	933	boost
O	934	939	group
O	939	940	,
O	941	953	respectively
O	954	955	(
O	955	956	P
O	957	958	<
O	959	960	.
O	960	964	0001
O	964	965	)
O	965	966	.

O	967	970	The
O	971	977	hazard
O	978	983	ratio
O	984	986	of
B-outcome	987	992	local
I-outcome	993	1003	recurrence
O	1004	1007	was
O	1008	1009	0
O	1009	1010	.
O	1010	1012	59
O	1013	1014	(
O	1014	1015	0
O	1015	1016	.
O	1016	1018	46
O	1019	1021	to
O	1022	1023	0
O	1023	1024	.
O	1024	1026	76
O	1026	1027	)
O	1028	1030	in
O	1031	1036	favor
O	1037	1039	of
O	1040	1043	the
O	1044	1049	boost
O	1049	1050	,
O	1051	1055	with
O	1056	1058	no
O	1059	1072	statistically
O	1073	1084	significant
O	1085	1096	interaction
O	1097	1100	per
O	1101	1104	age
O	1105	1110	group
O	1110	1111	.

O	1112	1115	The
B-outcome	1116	1124	absolute
I-outcome	1125	1129	risk
I-outcome	1130	1139	reduction
I-outcome	1140	1142	at
I-outcome	1143	1145	10
I-outcome	1146	1151	years
O	1152	1155	per
O	1156	1159	age
O	1160	1165	group
O	1166	1169	was
O	1170	1173	the
O	1174	1181	largest
O	1182	1184	in
O	1185	1193	patients
O	1194	1195	<
O	1195	1197	or
O	1197	1198	=
O	1199	1201	40
O	1202	1207	years
O	1208	1210	of
O	1211	1214	age
O	1214	1215	:
O	1216	1218	23
O	1218	1219	.
O	1219	1220	9
O	1220	1221	%
O	1222	1224	to
O	1225	1227	13
O	1227	1228	.
O	1228	1229	5
O	1229	1230	%
O	1231	1232	(
O	1232	1233	P
O	1234	1235	=
O	1236	1237	.
O	1237	1241	0014
O	1241	1242	)
O	1242	1243	.

O	1244	1246	As
O	1247	1248	a
O	1249	1255	result
O	1255	1256	,
O	1257	1260	the
B-outcome	1261	1267	number
I-outcome	1268	1270	of
I-outcome	1271	1278	salvage
I-outcome	1279	1291	mastectomies
O	1292	1295	has
O	1296	1300	been
O	1301	1308	reduced
O	1309	1311	by
O	1312	1314	41
O	1314	1315	%
O	1315	1316	.

B-outcome	1317	1323	Severe
I-outcome	1324	1332	fibrosis
O	1333	1336	was
O	1337	1350	statistically
O	1351	1364	significantly
O	1365	1374	increased
O	1375	1376	(
O	1376	1377	P
O	1378	1379	<
O	1380	1381	.
O	1381	1385	0001
O	1385	1386	)
O	1387	1389	in
O	1390	1393	the
O	1394	1399	boost
O	1400	1405	group
O	1405	1406	,
O	1407	1411	with
O	1412	1413	a
B-outcome	1414	1416	10
I-outcome	1416	1417	-
I-outcome	1417	1421	year
I-outcome	1422	1426	rate
O	1427	1429	of
B-iv-bin-percent	1430	1431	4
I-iv-bin-percent	1431	1432	.
I-iv-bin-percent	1432	1433	4
I-iv-bin-percent	1433	1434	%
O	1435	1441	versus
B-cv-bin-percent	1442	1443	1
I-cv-bin-percent	1443	1444	.
I-cv-bin-percent	1444	1445	6
I-cv-bin-percent	1445	1446	%
O	1447	1449	in
O	1450	1453	the
O	1454	1456	no
O	1457	1462	boost
O	1463	1468	group
O	1469	1470	(
O	1470	1471	P
O	1472	1473	<
O	1474	1475	.
O	1475	1479	0001
O	1479	1480	)
O	1480	1481	.

B-outcome	1482	1490	Survival
I-outcome	1491	1493	at
I-outcome	1494	1496	10
I-outcome	1497	1502	years
O	1503	1506	was
B-iv-bin-percent	1507	1509	82
I-iv-bin-percent	1509	1510	%
O	1511	1513	in
O	1514	1518	both
O	1519	1523	arms
O	1523	1524	.

O	1525	1530	After
O	1531	1532	a
O	1533	1539	median
O	1540	1546	follow
O	1546	1547	-
O	1547	1549	up
O	1550	1556	period
O	1557	1559	of
O	1560	1562	10
O	1562	1563	.
O	1563	1564	8
O	1565	1570	years
O	1570	1571	,
O	1572	1573	a
O	1574	1579	boost
O	1580	1584	dose
O	1585	1587	of
O	1588	1590	16
O	1591	1593	Gy
O	1594	1597	led
O	1598	1600	to
O	1601	1609	improved
O	1610	1615	local
O	1616	1623	control
O	1624	1626	in
O	1627	1630	all
O	1631	1634	age
O	1635	1641	groups
O	1641	1642	,
O	1643	1646	but
O	1647	1649	no
O	1650	1660	difference
O	1661	1663	in
O	1664	1672	survival
O	1672	1673	.
